Given a misdiagnosis rate of approximately 20% in Parkinson’s disease (PD), especially at early stages, imaging biomarkers are needed to improve the accuracy of clinical diagnosis.
A research group at the Clínica Universidad de Navarra, Madrid, Spain, compared 3T susceptibility-weighted magnetic resonance imaging (SW-MRI) of the substantia nigra and striatal 18F‐DOPA positron emission tomography (PET) for visualizing the biomarker nigrosome 1 in two groups: